Sep. 1 at 7:31 PM
$IBRX Big Pharma isn’t waiting for Phase 3 before writing multi-billion-dollar checks.
$LLY just demonstrated willingness to acquire biological/platform optionality very early. That does strengthen the argument that investors shouldn’t value innovative biotech solely on current drug revenue.
ANKTIVA commercialisation + geographic expansion + label expansion + pipeline/platform validation can create value without anyone buying the company. A takeover or major partnership is upside optionality.
And there’s another important fact:
$JNJ has explicitly targeted becoming the world’s No. 1 oncology company by 2030 with >
$50B oncology sales, while simultaneously pushing hard into bladder cancer. That makes IBRX strategically relevant either as a competitor or, theoretically, an acquisition/partnership asset.
